AbbVie Inc. (ABBV)
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.
Wall Street Analysts See AbbVie (ABBV) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
AbbVie Rewarded Patient Investors but Punished Those Who Bought on Good News
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Why AbbVie (ABBV) Outpaced the Stock Market Today
AbbVie (ABBV) closed at $265.85 in the latest trading session, marking a +1.15% move from the prior day.
5 High-Yield Dividend Stocks to Buy for October Income with Cash Flow to Spare
From a pharma giant rebuilding after a blockbuster patent loss to a pipeline partnership targeting double-digit distribution raises through 2027, these five stocks span wildly different industries yet share one thing: cash flow that keeps covering the check.
AbbVie joins US government pilot to test drug discount rebates
US drugmaker AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
5 Solid Dividend Stocks to Buy Now
An income portfolio built inside one sector carries one set of risks.
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?
